Pompe Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pompe Disease stocks.

Pompe Disease Stocks Recent News

Date Stock Title
Jul 1 SNY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Jul 1 SNY Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
Jul 1 BMRN Here’s Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
Jul 1 SNY Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Jul 1 SNY Sanofi reports findings from Phase II relapsing MS treatment trial
Jul 1 SNY Sanofi eyes German insulin investment of up to $1.6 billion, source says
Jun 29 SNY Where Will Novavax Be in 1 Year?
Jun 28 SNY PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
Jun 28 SNY 3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%
Jun 27 SNY Vigil Neuroscience jumps 34% as Sanofi invests $40M
Jun 27 SNY Formation Bio secures $372m funds for AI-driven drug platform
Jun 27 SNY Sanofi reports positive data from Phase III EoE treatment trial
Jun 26 SNY Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Jun 26 SNY Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Jun 26 SNY Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Jun 26 SNY Sanofi reports data from Phase II demyelinating polyneuropathy trial
Jun 26 SNY Pharma M&A: The top high value deals in 2023
Jun 25 SNY Sanofi reportedly seeking early bids for $20B consumer care spinoff
Jun 25 SNY Press Release: Availability of the Q2 2024 Aide-mémoire
Jun 25 SNY Sanofi Seeks Initial Offers for Its $20 Billion Consumer Arm
Pompe Disease

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

Browse All Tags